Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
22.87B
Market cap22.87B
Price-Earnings ratio
-17.65
Price-Earnings ratio-17.65
Dividend yield
Dividend yield
Average volume
3.46M
Average volume3.46M
High today
$107.80
High today$107.80
Low today
$98.90
Low today$98.90
Open price
$99.93
Open price$99.93
Volume
4.98M
Volume4.98M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$64.85
52 Week low$64.85

Stock Snapshot

Insmed Incorporated(INSM) stock is priced at $105.49, giving the company a market capitalization of 22.87B. It carries a P/E multiple of -17.65.

As of 2026-05-11, Insmed Incorporated(INSM) stock has fluctuated between $98.90 and $107.80. The current price stands at $105.49, placing the stock +6.7% above today's low and -2.1% off the high.

Insmed Incorporated(INSM) shares are trading with a volume of 4.98M, against a daily average of 3.46M.

During the past year, Insmed Incorporated(INSM) stock moved between $64.85 at its lowest and $212.75 at its peak.

During the past year, Insmed Incorporated(INSM) stock moved between $64.85 at its lowest and $212.75 at its peak.

INSM News

Benzinga 1d
Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?

Wall Street's momentum trade turned brutal for several large-cap names last week as weak earnings, cautious guidance and analyst downgrades sparked heavy sellin...

Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?
Simply Wall St 2d
If AI Healthcare Is The Next Breakout Read These Three Stocks

Artificial intelligence in healthcare sits at the crossroads of powerful data, rising care costs, and a world focused on inflation, energy shocks, and supply ch...

If AI Healthcare Is The Next Breakout Read These Three Stocks
TipRanks 3d
Insmed earnings selloff a buying opportunity, says H.C. Wainwright

H.C. Wainwright views the post-earnings selloff in shares of Insmed (INSM) as a buying opportunity. The “core Brinsupri launch thesis remains intact,” the analy...

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

More INSM News

Nasdaq 4d
Insmed Q1 2026 Earnings Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Insmed Q1 2026 Earnings Transcript
Simply Wall St 4d
Insmed Bronchiectasis Push With Ty Pennington May Expand Therapy Opportunity

Insmed (NasdaqGS:INSM) has launched a national "Suspect Bronchiectasis" awareness initiative with TV personality and patient advocate Ty Pennington. The compan...

Insmed Bronchiectasis Push With Ty Pennington May Expand Therapy Opportunity
Nasdaq 4d
Nasdaq 100 Movers: INSM, DDOG

In early trading on Thursday, shares of Datadog topped the list of the day's best performing components of the Nasdaq 100 index, trading up 31.2%. Year to date,...

Nasdaq 100 Movers: INSM, DDOG
Simply Wall St 7d
Rising Institutional Interest and Brinsupri Focus Might Change The Case For Investing In Insmed

In recent days, Insmed drew attention as Raymond James initiated coverage highlighting the early Brinsupri launch, RBC Capital raised its expectations, and Vang...

Rising Institutional Interest and Brinsupri Focus Might Change The Case For Investing In Insmed

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.